-Phase III trial enrolled a total of 480 patients with moderate to severe acne -Topline results expected in the second quarter 2025
After two weeks of treatment,GZR18 tablets resulted in an average weight reduction of up to 4.16%,with continued weight loss observed even after discontinuation.
Four Recipients\' Work From Israel,Sweden,Canada and South Africa Earns The Sigourney Award-2024 SEATTLE,Nov. 12,2024-- The Sigourney Award Trust annually recognizes outstanding work that advances ps
DataStream offers effortless access to ABI Research\'s first-party data via a single-pull API NEW YORK,Nov. 12,2024-- Global technology intelligence firm ABI Research is thrilled to announce the laun
HONG KONG,Nov. 13,2024-- The Shaw Prize presented its awards to five Shaw Laureates today at the 2024 Award Presentation Ceremony,held in the Hong Kong Convention and Exhibition Centre. Approximately
IRVINE,Calif.,Nov. 13,2024-- Zymo Research Corporation (Zymo Research),a leader in innovative life science solutions,announced today that it has filed claims in the United District Court for the Cent
